Tectonic Therapeutic has done well to advance its Fc-fusion protein candidate TX45 into a phase 2 study targeting patients ...

WATERTOWN, Mass. - Tectonic Therapeutic, Inc. (NASDAQ: TECX), a biotechnology company specializing in the development of therapeutic proteins and antibodies, announced today that it has entered into a ...

Tectonic Therapeutic (TECX) announced that it has entered into a securities purchase agreement for a private investment in public equity ...

Pursuant to the terms of the securities purchase agreement, at the closing of the PIPE, Tectonic will issue an aggregate of 3,689,465 shares of common stock at a price of $50.00 per share to fund ...

Tectonic expects to use net proceeds from the PIPE to fund the clinical development of TX45, clinical development of TX2100, discovery platform development as well as for working capital and other ...

Tectonic Therapeutic said the findings support the design and population for Phase 2 APEX trial, which will test TX45 in ...

Tectonic recently announced its third-quarter 2024 financial results, highlighting signif Phase 1a results support further development of TX000045 (“TX45”) for Group 2 Pulmonary Hypertension i ...

Tectonic Therapeutic, Inc. (NASDAQ: TECX) has announced a significant $185 million private placement financing. The private ...

After hours: February 6 at 4:38:44 p.m. EST ...